Cx3Cr1 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
CX3CR1 (C-X3-C Chemokine Receptor 1), also known as Fractalkine Receptor, is a G protein-coupled receptor (GPCR) that specifically binds the chemokine CX3CL1 (fractalkine). This receptor is predominantly expressed on microglia in the central nervous system and plays a critical role in modulating neuroinflammation and neuron-microglia communication.
The CX3CR1-CX3CL1 axis represents a unique signaling pathway that regulates microglial activation states, synaptic maintenance, and neuroprotection. Dysregulation of this pathway has been implicated in the pathogenesis of Alzheimer's Disease, Parkinson's Disease, and multiple sclerosis, making it a subject of intense therapeutic interest.
CX3CR1 is a Class A G protein-coupled receptor with seven transmembrane domains. The receptor contains an N-terminal extracellular domain that binds the chemokine CX3CL1 (fractalkine), seven transmembrane alpha helices, and an intracellular C-terminal tail. Structural studies show the receptor adopts the typical GPCR fold with ligand binding in the orthosteric site formed by transmembrane helices.
CX3CR1 mediates neuron-microglia communication through binding to membrane-bound or soluble fractalkine (CX3CL1). This signaling pathway:
The study of Cx3Cr1 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH. Mechanisms underlying inflammation in neurodegeneration. Cell. 2010;140(6):918-934. DOI:10.1016/j.cell.2010.02.016
Heneka MT, Carson MJ, El Khoury J, et al. Neuroinflammation in Alzheimer's disease. Lancet Neurol. 2015;14(4):388-405. DOI:10.1016/S1474-4422(1570016-5
Ransohoff RM. How neuroinflammation contributes to neurodegeneration. Science. 2016;353(6301):777-783. DOI:10.1126/science.aag2590
Song WM, Colonna M. The identity and function of microglia in neurodegeneration. Nat Immunol. 2018;19(10):1048-1058. DOI:10.1038/s41590-018-0212-1
Wolf Y, Yona S, Kim KW, Jung S. Microglia, seen from the TNF side. Nat Rev Immunol. 2017;17(1):49. DOI:10.1038/nri.2016.144
Prinz M, Priller J. The role of peripheral immune cells in the CNS in steady state and disease. Nat Neurosci. 2017;20(2):136-144. DOI:10.1038/nn.4475
Deczkowska A, Amit I, Schwartz M. Microglial immune checkpoint mechanisms. Nat Neurosci. 2018;21(6):779-781. DOI:10.1038/s41593-018-0144-y
Keren-Shaul H, Spinrad A, Weiner A, et al. A unique microglia type associated with restricting development of Alzheimer's disease. Cell. 2017;169(7):1276-1290.e17. DOI:10.1016/j.cell.2017.05.018